周二盘中，诺瓦瓦克斯医药股价大跌5.75%，引发市场关注。这一跌势主要受到花旗银行最新研究报告的影响。
据悉，花旗银行研究部开始对诺瓦瓦克斯进行研究，给予"卖出/高风险"评级，目标价为6美元。分析师指出，诺瓦瓦克斯过于专注于呼吸系统疫苗，而该市场的疫苗接种率正在下降。特别值得注意的是，COVID-19疫苗市场正在逐年萎缩，整体下降10%，65岁以下人群更是下降12%。
此外，花旗还提到，诺瓦瓦克斯在呼吸道疫苗领域面临着来自辉瑞、莫德纳和葛兰素史克等老牌企业的激烈竞争。值得注意的是，FDA批准诺瓦瓦克斯的COVID疫苗（Nuvaxovid）仅适用于65岁以上的成年人和12-64岁的高危人群，而竞争对手的疫苗则没有这些限制，这进一步加大了诺瓦瓦克斯的市场压力。这些因素共同导致了投资者对公司前景的担忧，引发了股价的大幅下跌。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.